AU
UK
CA
NZ
IND
US
Key Highlights• Strong headline growth deserves deeper analysis.• Capital allocation remains the key investment variable.• Balance-sheet strength matters more in uncertain markets.• Revenue quality is as important as revenue growth.• Long-term investors should focus on cash generation.Financial markets often reward growth stories, but durable …
Key Highlights• Strong headline growth deserves deeper analysis.• Capital allocation remains the key investment variable.• Balance-sheet strength matters more in uncertain markets.• Revenue quality is as important as revenue growth.• Long-term investors should focus on cash generation.Financial markets often reward growth stories, but durable …
Key Highlights
Aditxt (NASDAQ: ADTX) announced a senior secured note purchase agreement involving its wholly owned subsidiary Ignite Proteomics LLC.
PMGC Holdings (NASDAQ: ELAB) recently emphasized its ITAR-registered and AS9100-certified manufacturing capabilities as interest in space infrastructure and satellite-related projects continues to grow.
Basel Medical Group (NASDAQ: BMGL) announced that it will implement a 1-for-12 reverse stock split effective June 22, 2026.
CervoMed (NASDAQ: CRVO) announced a private placement expected to generate approximately $10.5 million in upfront gross proceeds.
Rafael Holdings (NYSE: RFL) announced the successful completion of the Last Patient Last Visit milestone for the final 96-week treatment period in its global Phase 3 TransportNPC clinical trial.
Polyrizon (NASDAQ: PLRZ) announced that the European Patent Office published its patent application covering the company's Trap & Target mucoadhesive nasal-delivery technology.
Dianthus Therapeutics (NASDAQ: DNTH) is in focus following a major development in the neuro-immunology sector. Sanofi (NASDAQ: SNY) announced the termination of its Phase 3 MOBILIZE trial evaluating riliprubart after the study failed to demonstrate sufficient clinical efficacy.
Please wait processing your request...